ERBB2 and non-small cell lung carcinoma: The DESTINY-Lung01 and DESTINY-Lung02 trials were multicenter, single-arm, phase II studies evaluating the efficacy of T-DXd in patients with unresectable or metastatic NSCLC carrying HER2 mutations or overexpression.